Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Petersdorf, S; Kopecky, K; Stuart, RK; Larson, RA; Nevill, TJ; Stenke, L; Slovak, ML; Tallman, MS; Willman, CL; Erba, H; Appelbaum, FR

Published Date

  • November 20, 2009

Published In

Volume / Issue

  • 114 / 22

Start / End Page

  • 326 - 327

Published By

Pages

  • 2

International Standard Serial Number (ISSN)

  • 0006-4971

Conference Name

  • 51st Annual Meeting of the American-Society-of-Hematology

Conference Location

  • New Orleans, LA

Conference Start Date

  • December 5, 2009

Conference End Date

  • December 8, 2009